From Neonatal Encephalopathy to Adult Survival: Revisiting the Natural History of D-Bifunctional Protein Deficiency

U Diaz-Moreno1, S L C Brothwell2, A Darling3

  • 1Department of Paediatric Inherited Metabolic Medicine, Great Ormond Street Hospital, London, UK.

Insights

D-bifunctional protein deficiency (DBP-D) is a rare peroxisomal disorder. This study shows survival into adulthood is possible, especially with normal very long-chain fatty acids (VLCFAs), highlighting the need for early genetic testing.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • D-bifunctional protein deficiency (DBP-D) is a rare autosomal recessive peroxisomal disorder.
  • Pathogenic variants in HSD17B4 cause DBP-D, with a broad clinical spectrum.
  • Limited data exist on long-term outcomes for DBP-D patients.

Purpose of the Study:

  • To comprehensively review the clinical, biochemical, neuroimaging, neurophysiological, and genetic data of DBP-D patients.
  • To characterize long-term outcomes and identify factors influencing survival and phenotype.
  • To expand the understanding of the clinical and genetic landscape of DBP-D.

Main Methods:

  • Retrospective, multicentre review of 26 DBP-D patients (1982-2024) across UK and Spanish centers.
  • Systematic collection of clinical, biochemical, neuroimaging, neurophysiological, and genetic data.
  • Literature review to contextualize findings.

Main Results:

  • High early mortality (77% before age 2), but 3 patients survived beyond 5 years, including one adult.
  • Normal or mildly elevated very long-chain fatty acids (VLCFAs) were associated with survival beyond 2 years.
  • Neuroimaging varied by severity: polymicrogyria/cysts in neonatal-onset, cerebellar atrophy in later-onset survivors.
  • 14 novel HSD17B4 alleles were identified.

Conclusions:

  • Survival into adulthood is possible in DBP-D.
  • Normal or mildly elevated VLCFAs correlate with milder phenotypes and better prognosis.
  • Early molecular testing is crucial for diagnosis, prognosis, and management, even with normal VLCFAs.